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Abstract:
Background:
Actinic cheilitis, herpes labialis and lip cancer are relatively common conditions presenting on the lips associated with exposure to periods of sun
exposure and thereby ultraviolet radiation.
Objective:
This systematic review aimed to determine the efficacy of the application of sunscreen-containing lip-protecting agents (LPA) in the prevention of
actinic cheilitis (AC), recurrent herpes labialis (RHL) and lip cancer (LC).
Methods:
This review was conducted in accordance with the PRISMA guidelines and registered with the PROSPERO database. A literature search was
conducted using SCOPUS, Google Scholar, Medline (Ovid), Pubmed, CINAHL, Cochrane Library databases and manual search using search
terms actinic cheilitis (AC), recurrent herpes labialis (RHL) and lip cancer (LC) along with lip protecting agents and their variations as keywords.
A total of 1,567 papers were yielded. Of them, nine studies were eligible for qualitative data synthesis.
Results:
Nine articles (3 AC, 5 RHL, 1 LC) were deemed eligible and thus selected for qualitative synthesis. Three studies on AC identified approximately
21.7% lower prevalence of lesions when some form of lip protection was used. Eighty percent of studies on RHL identified that the application of
LPA is effective in preventing RHL. Subjects who applied LPA more than once daily only had half the risk of having LC compared to those who
applied once daily.
Conclusion:
This review of randomised controlled trials (RCTs) and observational studies supports the use of LPA as an effective method in preventing lip-
associated lesions. Further,  RCTs and observational studies should aim at determining a definitive LPA application regime and optimal SPF
strength to prevent lip-associated lesions.
This systematic review was registered with the International Prospective Register of Systematic Reviews (PROSPERO): Registration Number -
CRD42020177484. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020177484
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1. INTRODUCTION
Ultraviolet Radiation (UVR) is found in abundance in the
environment,  contributing  to  a  spectrum  of  skin  lesions
including  inflammatory lesions,  degenerative  aging and  skin
*  Address  correspondence  to  this  author  at  the  College  of  Medicine  and
Dentistry, James Cook University, Cairns, Australia; Tel: 0410462827;
E-mail: dileep.sharma@jcu.edu.au
cancers [1]. Actinic cheilitis, herpes labialis and lip cancer are
relatively common conditions presenting on the lips  that  can
cause  considerable  morbidity,  and  less  frequently,  mortality
[2]. The common major etiological factor for those lip lesions
is exposure to ultraviolet radiation. Those who experience long
periods  of  sun  exposure,  often  due  to  occupational  or
recreational  reasons,  are  vulnerable  to  the  harmful  effects  of
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UVR [1]. Yet, the lips are frequently neglected when it comes
to sun protection [1]. Knowledge from existing studies [3, 4] of
the  lip  lesions  predominantly  surrounds  the  pharmacological
aspect  of  lesion  resolution.  However,  to  date,  there  is  a
knowledge  gap  in  the  aspects  concerning  prevention.
Actinic  Cheilitis  (AC)  is  a  potentially  malignant  oral
disorder  that  frequently  affects  the  vermillion  border  of  the
lower lip, with a global prevalence of 0.45% to 2.4% [5]. UVR
is the predominant  etiological  factor  for  AC development.  A
variety of premalignant lesions are found in patients exposed to
UVR,  including  AC.  Ultraviolet  A  and  B  promote  local
immunosuppression  and  changes  in  proteins,  contributing
indirectly  to  dysplastic  changes.  The  production  of  reactive
oxygen  species  induced  by  UVA  contributes  to  oxidative
stress, which causes cellular damage that leads to the onset of
AC [2]. Clinically, the lower lip often displays scales, fissures
and  erosions  [6].  In  advanced  disease,  blurred  demarcation
between  the  lip  vermillion  border  and  skin  is  observed,  in
addition  to  atrophic,  erosive  or  keratotic  plaques  [6,  7].  The
keratotic patches may progressively thicken and ulcerate, that
are suggestive of malignant transformation [6, 7]. AC occurs
more  frequently  in  those  with  fair  complexions,  males,  the
elderly, those who live at high altitudes, and most significantly,
those  with  high  exposure  to  the  sun  [8  -  10].  Other  factors
linked to the malignant transformation of AC include tobacco
smoking and genetic predisposition [8 - 10].
Although some contributing factors related to AC, such as
skin  complexion  and  occupation,  may  be  unmodifiable,
sunscreen-containing LPAs should still be applied due to their
known prophylactic and alleviating effects on AC [7]. Savage
et al. have outlined a prevention protocol for AC. This includes
limiting  sun  exposure,  wearing  a  broad-brimmed  hat  and
application  of  a  broad-spectrum  sunscreen  with  a  Sun
Protection Factor (SPF) higher than 30 applied every two hours
when outdoors [11]. Despite UVR being the principal cause of
AC,  there  have  been  limited  reports  on  the  effectiveness  of
sunscreen  in  the  prevention  of  AC.  Yet,  its  analogous
counterpart  affecting  the  skin,  actinic  keratoses,  has  been
widely  studied  [12  -  14].
Herpes  labialis,  commonly  known  as  “cold  sore”,  is  the
reactivation of viral infection caused by Herpes Simplex Virus
(HSV) type 1 that manifests primarily on the lips and perioral
region  [15].  HSV  is  mainly  transmitted  through  oral-to-oral
contact  with a  virus-shedding individual  [16].  It  is  estimated
that  around  16%  to  45%  of  the  global  population  has  been
infected with HSV [17]. Once acquired, it can cause herpetic
gingivo-stomatitis  and  remains  dormant  in  nerve  tissues  to
reactivate as Recurrent Herpes Labialis (RHL) at any age [18].
RHL  lesions  can  be  presented  in  grouped  vesicles  and
erythema,  causing discomfort  or  pain [19].  It  has an average
incidence  of  1.6  and  an  average  prevalence  of  2.5  per  1,000
population  annually  [18].  About  one-third  of  patients  with  a
history of RHL will experience at least one recurrence in their
lifetime  [20].  Recurrence  can  be  induced  by  a  variety  of
intrinsic and extrinsic factors, including exposure to ultraviolet
radiation,  high  fever,  trauma,  emotional  stress  and  immune
suppression [18].
Studies have been conducted on herpes labialis but most of
them focused on the pharmacological aspect of treatment, such
as  the  efficacy  of  different  types  and  forms  of  antiviral
medications  [21]  Potential  genetic  components  that  may
influence  the  recurrence  of  herpes  labialis  have  also  been
studied [13].  However,  there are a limited number of studies
exploring the effect  of  ultraviolet  radiation independently on
Recurrent Herpes Labialis (RHL). Most of the studies utilised
sunscreen-containing  LPAs  as  a  placebo  in  their  studies
without investigating the potential protective effect of LPAs.
Lip cancer (LC) has a prevalence of 12 per 100,000 and an
incidence of 4 per 100,000 [22]. The vermilion border of the
lips,  especially  the  lower  lip  can  be  directly  exposed  to
sunlight, and hence carries a high risk of developing lip cancer
[23].  The  main  histological  types  of  LC  are  squamous  cell
carcinoma  and  basal  cell  carcinoma  [24].  As  squamous  cell
carcinoma  is  strongly  related  to  cumulative  constant  UV
exposure,  LPAs  with  UV  barriers  are  of  importance  in
preventing  the  occurrence  of  lip  cancers  [25].
The objective of this systematic review is to analyse and
critically  appraise  current  literature  to  determine  the
effectiveness  of  sun  protection  factor  containing  LPAs
(commercial and test formulation) in the prevention of actinic
cheilitis, herpes labialis and lip cancer lesions.
2. METHODS
2.1. Protocol and Registration
This  systematic  review  was  registered  with  the
International  Prospective  Register  of  Systematic  Reviews
(PROSPERO):
https://www.crd.york.ac.uk/prospero/display_record.php?ID=C
RD42020177484  (registration  number  CRD42020177484).
The  Preferred  Reporting  Items  for  Systematic  Reviews  and
Meta-Analyses (PRISMA) guidelines were used to conduct this
review [26].
2.2. Search Strategy and Selection Criteria
A comprehensive literature search for studies of each lip
condition (AC, RHL, LC) was conducted using the following
electronic  databases:  SCOPUS,  Google  Scholar,  Medline,
PubMed, The Cumulative Index to Nursing and Allied Health
Literature  (CINAHL),  and  the  Cochrane  Library  on  4  April
2020. A full list of the search terms used for each lip condition
in each database is provided in Table (1). A manual search for
articles  was  also  conducted.  Predetermined  inclusion  and
exclusion criteria were used to filter out studies relevant to our
review. The inclusion criteria were human studies published in
English  language,  full-text  availability,  peer-reviewed,
randomised  controlled  trials,  observational  studies,  and
focusing on the prevention of lip-associated lesions through the
use of an LPA. The exclusion criteria were articles published in
other languages than English, full-text unavailable, a non-peer
review, case reports, idea, editorial and anonymous survey, use
of  LPA containing an antiviral,  and animal  studies.  No limit
was placed on the date of publication of the articles. A total of
two  studies  (2  AC,  0  RHL,  0  LC)  were  excluded  due  to
inaccessible full-text. Of the studies selected, duplicates were
removed,  and  the  remaining  studies  were  reviewed  for
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relevance according to title, abstract and full-text, as illustrated
in (Fig. 1). Articles that were excluded after full-text screening
did not mention lesions occurring on the lips specifically and
did not report the prevalence of the lip lesions. Articles that did
not concern lip protection but general sun protection only were
also excluded.
Table 1. Databases and search terms used for literature search.
Database
Lip Condition and Search terms
RHL AC LC
Scopus (sunscreen OR sunblock OR “skin protection”
OR “sun protection” OR “UV protection” OR
“sun filter” OR photoprotect* OR “sun tan
lotion” OR “lip balm” OR “lip care” OR lotion
or “lip cream” or lipstick)
AND (“cold sore” OR “herpes labialis” OR
“herpes simplex labialis” OR “oral herpes” OR
“herpetic gingivostomatitis” OR “Recurrent
gingivostomatitis” OR “recurrent herpes” OR
“fever blisters”)
(sunscreen OR sunblock OR “skin protection”
OR “sun protection” OR “UV protection” OR
“sun filter” OR photoprotect* OR “sun tan
lotion” OR “lip balm” OR “lip care” OR lotion
or “lip cream” or lipstick) AND
(“solar cheilitis” OR “actinic cheilitis” OR
“solar cheilosis” OR “actinic cheilosis” OR
“actinic keratosis” OR “actinic keratosis” OR
“solar keratosis” OR “sailor’s lip” OR “farmer’s
lip” OR “farmer lip”)
(lip OR labial OR mouth)
AND
sunscreen OR sunblock OR (“skin
protection” OR “sun protection” OR
“UV protection” OR “sun filter” OR
photoprotect* OR “sun tan lotion” OR
“lip balm”
OR “lip care” OR lotion or “lip cream”
or lipstick)
AND
(cancer OR neoplasm OR malignan*
OR carcinoma)
Medline Radiation-Protective Agents OR Sunscreening
Agents OR sunblock OR skin protection OR
sun protection OR UV protection OR sun filter
OR photoprotection OR sun tan lotion OR lip
balm OR lip care OR lotion OR lip cream OR
lipstick AND Herpes Labialis OR cold sore OR
herpes simplex labialis OR oral herpes OR
herpes gingivostomatitis OR Recurrent Herpes
Gingivostomatitis OR fever blisters
Radiation-Protective Agents OR Sunscreening
Agents OR sunblock OR skin protection OR sun
protection OR UV protection OR sun filter OR
photoprotection OR sun tan lotion OR lip balm
OR lip care OR lotion OR lip cream OR lipstick
AND Cheilitis OR solar cheilitis OR actinic
cheilitis OR solar cheilosis OR actinic cheiloses
OR Keratosis, Actinic OR actinic keratosis OR
solar keratosis OR solar keratosis OR sailors lip
OR farmers lip OR farmer lip
Lip OR labial OR Mouth AND
Radiation-Protective Agents OR
Sunscreening Agents OR sunblock OR
skin protection OR sun protection OR
UV protection OR sun filter OR
photoprotection OR sun tan lotion OR
lip balm OR lip care OR lotion OR lip
cream OR lipstick AND cancer
OR neoplasms OR carcinoma OR
malignancy
Pubmed sunscreen OR sunblock OR “skin protection”
OR “sun protection” OR “UV protection” OR
“sun filter” OR photoprotect* OR “sun tan
lotion” OR “lip balm” OR “lip care” OR lotion
or “lip cream” or lipstick AND
“cold sore” OR “herpes labialis” OR “herpes
simplex labialis” OR “oral herpes” OR
“herpetic gingivostomatitis” OR “Recurrent
gingivostomatitis” OR “recurrent herpes” OR
“fever blisters”
sunscreen OR sunblock OR “skin protection”
OR “sun protection” OR “UV protection” OR
“sun filter” OR photoprotect* OR “sun tan
lotion” OR “lip balm” OR “lip care” OR lotion
or “lip cream” or lipstick AND “solar cheilitis”
OR “actinic cheilitis” OR “solar cheilosis” OR
“actinic cheilosis” OR “actinic keratosis” OR
“solar keratosis” OR “sailor’s lip” OR “farmer’s
lip” OR “farmer lip”
sunscreen OR sunblock OR “skin
protection” OR “sun protection” OR
“UV protection” OR “sun filter” OR
photoprotect* OR “sun tan lotion” OR
“lip balm” OR “lip care” OR lotion or
“lip cream” or lipstick AND
lip OR labial OR mouth AND
cancer OR neoplasm OR malignan*
OR carcinoma
Cochrane “cold sore” OR “herpes labialis” OR “herpes
simplex labialis” OR “oral herpes” OR
“herpetic gingivostomatitis” OR “Recurrent
gingivostomatitis” OR “recurrent herpes” OR
“fever blisters” in Title Abstract Keyword
AND "sunscreen" OR "sunblock" OR “skin
protection” OR “sun protection” OR “UV
protection” OR “sun filter” OR photoprotect*
OR “sun tan lotion” OR “lip balm” OR “lip
care” OR "lotion" OR “lip cream” or "lipstick"
in Title Abstract Keyword - (Word variations
have been searched)
“solar cheilitis” OR “actinic cheilitis” OR “solar
cheilosis” OR “actinic cheilosis” OR “actinic
keratosis” OR “actinic keratosis” OR “solar
keratosis” OR “sailor’s lip” OR “farmer’s lip”
OR “farmer lip” in Title Abstract Keyword
AND "sunscreen" OR "sunblock" OR “skin
protection” OR “sun protection” OR “UV
protection” OR “sun filter” OR photoprotect*
OR “sun tan lotion” OR “lip balm” OR “lip
care” OR "lotion" OR “lip cream” or "lipstick"
in Title Abstract Keyword - (Word variations
have been searched)
"lip" OR "labial" OR "mouth" in Title
Abstract Keyword
AND "cancer" or "neoplasm" OR
malignan* OR carcino* in Title
Abstract Keyword
AND "sunscreen" OR "sunblock" OR
“skin protection” OR “sun protection”
OR “UV protection” OR “sun filter”
OR photoprotect* OR “sun tan lotion”
OR “lip balm” OR “lip care” OR
"lotion" OR “lip cream” or "lipstick"
in Title Abstract Keyword - (Word
variations have been searched)
Cinahl lip OR labial OR mouth OR (MH "Lip") AND
sunscreen OR sunblock OR “skin protection”
OR “sun protection” OR “UV protection” OR
“sun filter” OR photoprotect* OR “sun tan
lotion” OR “lip balm” OR “lip care” OR (MH
"Sunscreening Agents") AND “cold sore” OR
“herpes labialis” OR “herpes simplex labialis”
OR “oral herpes” OR “herpes
gingivostomatitis” OR “Recurrent
gingivostomatitis” OR “recurrent herpes” OR
“fever blisters”
lip OR labial OR mouth OR (MH "Lip") AND
sunscreen OR sunblock OR “skin protection”
OR “sun protection” OR “UV protection” OR
“sun filter” OR photoprotect* OR “sun tan
lotion” OR “lip balm” OR “lip care” OR (MH
"Sunscreening Agents") AND “solar cheilitis”
OR “actinic cheilitis” OR “solar cheilosis” OR
“actinic cheiloses” OR “actinic keratosis” OR
“actinic keratoses” OR “solar keratosis” OR
“solar keratoses” OR “sailor’s lip” OR “farmer’s
lip” OR “farmer lip” OR (MH "Keratosis,
Actinic") OR (MH "Cheilitis")
lip OR labial OR mouth OR (MH
“Lip”) AND sunscreen OR sunblock
OR “skin protection” OR “sun
protection” OR “UV protection” OR
“sun filter” OR photoprotect* OR “sun
tan lotion” OR “lip balm” OR “lip
care” OR (MH “Sunscreening
Agents”)
AND cancer OR neoplasm OR
“malignan*” OR carcinoma OR (MH
“Lip Neoplasms”)
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Google
Scholar
sunscreen OR sunblock OR “skin protection”
OR “sun protection” OR “UV protection” OR
“sun filter” OR photoprotect* OR “sun tan
lotion” OR “lip balm” OR “lip care” OR lotion
or “lip cream” or lipstick OR Radiation-
Protective Agents OR Sunscreening Agents
AND “cold sore” OR “herpes labialis” OR
“herpes simplex labialis” OR “oral herpes” OR
“herpetic gingivostomatitis” OR “Recurrent
gingivostomatitis” OR “recurrent herpes” OR
“fever blisters”
sunscreen OR sunblock OR “skin protection”
OR “sun protection” OR “UV protection” OR
“sun filter” OR photoprotect* OR “sun tan
lotion” OR “lip balm” OR “lip care” OR lotion
or “lip cream” or lipstick OR Radiation-
Protective Agents OR Sunscreening Agents
AND “solar cheilitis” OR “actinic cheilitis” OR
“solar cheilosis” OR “actinic cheilosis” OR
“actinic keratosis” OR “solar keratosis” OR
“sailor’s lip” OR “farmer’s lip” OR “farmer lip”
sunscreen OR sunblock OR “skin
protection” OR “sun protection” OR
“UV protection” OR “sun filter” OR
photoprotect* OR “sun tan lotion” OR
“lip balm” OR “lip care” OR lotion or
“lip cream” or lipstick OR Radiation-
Protective Agents OR Sunscreening
Agents AND lip OR labial OR mouth
AND cancer OR neoplasm OR
malignan* OR carcinoma
2.3. Qualitative Synthesis
Articles  selected  for  full-text  review  were  distributed
between two groups of members. SM, MR and AVS analysed
the  first  half  of  the  articles,  and  AS  and  ST  reviewed  the
second half of the articles. The inclusion and exclusion criteria
were used to select studies relevant for review. An electronic
Microsoft Excel spreadsheet was created to extract data from
the  studies  following  the  PICOS  framework  (population,
intervention, comparison, outcomes and study type), along with
the  type  of  lip-protective  agent  used  (Table  2).  When
disagreement  arose  between  two  reviewers,  a  third  reviewer
was consulted and a consensus was reached. The final analysis
of the data was verified by each author (SM, MR, AVS, AS,
ST) and was reaffirmed by the senior authors (AA, DS).
Table 2. Included studies after full-text review and reported findings.
Actinic cheilitis
Author. Year. Location Study Type Population Intervention/Lip Product
Studied
Measured Outcome
de Oliveira RA, da
Silva L, et al. 2014.




N/A Prevalence of AC with sun
block was 0%.





Gonzaga A, et al. 2019
Unknown Randomised
Controlled Trial
23 subjects with AC. Fludroxycortide and Lip
sunscreen
LS only patients presented 1
with complete improvement,
4 with partial improvement
and 3 with no change. F+LS
patients- 5 with total
remission, 7 with partial
improvement, 3 with no
changes.
dos Santos R, de
Oliveira R, et al. 2018.
Brazil Cross-sectional study 201 male subjects. N/A 57.9% had AC with lip
protection.
36.2% had AC without lip
protection.
Recurrent Herpes labialis









A sunblock stick containing
Mexoryl SX, Eusolex 6300 and
Parsol 1789.
10 out of 19 subjects had
RHL after using vehicle but
no RHL after sunblock.
Mazzarello V, Ferrari





20 adult subjects (8
males, 12 females)
serving as their own
controls.
Sun protecting lipstick with SPF
30 for 30 days. Application
every 2 hours, after eating,
drinking, smoking, and
swimming
















Sunscreen (lipstick and lotion
form) with SPF 15. Either UVA
or UVB sunscreen-containing
PABA and benzophenone.
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females and 8 males)
with a history of
recurrent herpes
labialis at least once




Sunscreen with SPF 15 (Total
Eclipse AB)
With placebo and UV, 27/38
(71%) developed RHL.
With sunscreen and UV, no
RHL developments were
observed, except 1/35 shed
virus at exposure site.
Shulman J, Carpenter







Army-issued wax stick type lip
protectant and commercially
available lip protectants (not
specified)
RHL in 4% of subjects with
prevalence rates as high as
10% of soldiers not using lip
protectants.
Lip protectant reported by
77% of subjects, with non-
users having 4 times higher
prevalence of RHL than
users.
Lip Cancer










74 females with lip
cancer, 105 controls
Lip protectant covering Subjects with higher exposure
to average UVR flux (at or
above 430) with less than one
application of lip protection a
day had the highest risk of
LC.
2.4. Assessment of Risk of Bias in Individual Studies
The risk  of  bias  and  level  of  evidence  for  each  included
study  was  assessed  by  two  of  the  reviewers  (SM,  AS,  AVS,
MR,  ST)  independently.  Differences  in  judgment  were
resolved  through  mediation  by  a  third  reviewer.  To  ensure
reliability of the results, the final results were checked through
a group discussion involving all members of the group until a
consensus was reached. The Cochrane Collaboration tool for
assessing the risk of bias was used for Randomised Controlled
Trials (RCT) and ROBINS-I (Risk Of Bias In Non-randomised
Studies- of Interventions) was used for non-randomised studies
[27  -  29].  The  Cochrane  Collaboration  tool  evaluates  six
sources  of  bias:  Random  Sequence  Generation,  Allocation
Concealment, Blinding of Participants and Personnel, Blinding
of Outcome Assessment, Incomplete Outcome Data, Selective
Reporting  [27].  In  ROBINS-I,  sources  of  bias  were  divided
into  3  domains:  pre-intervention,  at  intervention  and  post-
intervention [28]. Each domain was assessed individually for
low,  moderate,  serious  or  critical  risk  [28].  Results  of  all
domains  were  then  analysed  to  determine  the  overall  risk  of
bias for the specific study [28]. The risk of bias of each study
was summarised and tabulated (Table 3).
3. RESULTS
A  total  of  1,567  articles  were  identified  via  databases
(1556  articles)  and  manual  searches  (11  articles)  (Fig.  1).
Articles were screened in the order of title,  abstract,  and full
text.  Duplicate  articles  were  removed,  thus  yielding  1076
articles  for  eligibility  screening.  Nine  (3  AC,  5  RHL,  1  LC)
articles were deemed eligible and thus selected for qualitative
synthesis (Table 2).
Table 3. Risk of bias assessment of non-randomised studies using ROBINS-I tool.


































Low Low Low Low Moderate Low Low Moderate
dos Santos, R.
2018 Low Low Low Low Low Low Low Low
Shulman, J.
1992 Low Moderate Serious Moderate Low Moderate Low Serious
Pogoda, J.
1996 Low Low Low Low Low Low Low Low
  2
 
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Fig. (1). PRISMA Flow Diagram illustrating literature search process.
Five studies related to RHL were included for review [30 -
34]. All studies assessed some form of LPA in the prevention
of RHL. Mills et al. [30], Rooney et al. [32], Mazzarello et al.
[34], and assessed the use of a sunscreen-containing LPA in the
prevention of RHL. Duteil et al. [31] studied a form of LPA in
the prevention of RHL, however, the SPF of the product was
not stated. Similarly, Shulman et al. [33] did not state the SPF
in the LPA used. There was a significant variation across the
studies in terms of the number of participants used. All studies,
except Shulman et al. [33], which was an observational study,
consisted of a control group. The control group in the Duteil et
al. [31] was given a lip protectant without sunlight-absorbing
filters.  Mills  et  al.  [30]  and  Rooney  et  al.  [32]  provided  a
placebo to their control groups. The participants in the study
conducted  by  Mazzarello  et  al.  [34]  posed  as  both  the  study
and control  group.  In the study conducted by Shulman et  al.
[33],  the  control  group received no LPA.  All  studies,  except
Shulman et al. [33], conducted a follow-up or review with their
study  participants  either  in  the  form  of  a  questionnaire  or
clinical  exam.
Three articles related to AC were included for review. In
the studies conducted by de Oliveira Ribeiro et al. [2] and dos
Santos  et  al.  [35],  the  prevalence  of  AC  was  conducted
amongst a group of participants.  The participant size of both
studies  consisted  of  greater  than  200  participants.  In  these
studies,  however,  it  was  not  specified  whether  follow-up
appointments were conducted and what type of LPA was used.
The study conducted by de Oliveira Bezerra et al. [21], which
consisted  of  23  participants,  assessed  the  efficacy  of
fludroxycortide,  a  topical  corticosteroid,  combined  with  lip
sunscreen in the treatment of AC [21]. In this particular study,
there  was  also  a  control  group  that  was  treated  with  lip
sunscreen  alone.  Follow-ups  were  conducted  weekly  [21].
Only a single study related to LC was deemed eligible for
inclusion in this review. The study conducted by Pogoda et al.
[36] was an observational study, which explored the hypothesis
that the incidence of lip cancer was greater in men partly due to
the frequent  use of  lip protection by women. This study was
conducted  in  the  United  States  in  1996  and  consisted  of  74
women diagnosed with lip cancer and a control group of 105
participants [36]. The study was conducted via an interview or
verbatim questionnaire [36]. The type of LPA studied was not
stated as the main indication was to assess LC prevalence in
women  due  to  frequent  wear  of  lip  covering,  a  potential
protecting behaviour against sun exposure [36]. No follow-up
or reviews were conducted [36].
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Table  4.  Risk  of  bias  assessment  for  randomised  studies  using  the  Cochrane  Collaboration  Tool  (+  indicates  low  risk,  -
indicates high risk, ? indicates not enough information).
- De Oliveira Bezerra,2019 Duteil, 1998 Mazzarello, 2019 Mills, 1987 Rooney, 1991
Randomised sequence generation (selection bias) ? ? + + +
Allocation concealment (selection bias) ? ? ? + ?
Blinding of participants and personnel (performance bias) + + + + +
Blinding of outcome assessment (detection bias) + + + + +
Incomplete outcome data (attrition bias) - + + + +
Selective reporting (reporting bias) + + + + +
Other bias + + + - +
3.1. Risk of Bias in Included Studies
The Cochrane Collaboration tool for assessing the risk of
bias and ROBINS-I were used to determine the risk of bias and
evidence  quality  for  RCTs  and  observational  studies
respectively.  The risk of  bias  of  each study was summarised
and tabulated (Tables 3 and 4).
Only two observational studies of the nine overall included
studies  resulted in  a  low risk  of  bias  across  all  domains  [35,
36].  However,  no  study  was  deemed  of  high  enough  risk  of
bias to be excluded from this systematic review.
3.2. Quality Assessment of Included Studies
An overall low quality of evidence implies that the study
was excluded from the review. Moderate overall gradings were
given to  AC and RHL,  however,  due to  lack of  information,
grading could not be performed for LC.
GRADE  assessment  demonstrated  that  all  included
observational studies and RCTs exhibited a moderate quality of
evidence.  The  observational  studies  were  automatically
downgraded  due  to  weaker  evidence  compared  to  RCTs.
Evidence  from other  studies  was  predominantly  downgraded
due  to  risk  of  bias,  most  significantly  relating  to  lack  of
blinding  of  participants  or  outcome  assessors.  Heterogeneity
across  the  combined  studies  of  AC  and  RHL  was  moderate,
however, LC studies could not be assessed against this factor.
Failure to calculate sample sizes and inadequate sample sizes
were also major contributors resulting in the downgrading of
evidence.
3.3. Effects of Interventions
3.3.1. Recurrent Herpes Labialis (RHL)
Five articles related to RHL satisfied our inclusion criteria
[30 - 34]. They examined the prevalence of RHL with the use
of LPA. All studies involved patients with a history of at least
one RHL recurrence in a year.
Mills  et  al.  [30]  conducted  an  RCT with  a  high  level  of
evidence on 51 volunteers in 3 ski resorts in the United States
(41  men  and  10  women).  The  participants  applied  either  an
LPA  with  a  lotion  containing  SPF  15  (n=24)  or  a  placebo
(n=27)  while  being  observed  for  one  week  between  January
and April 1984. They reported a 12% prevalence of RHL (6 of
51  subjects),  equally  divided  between  the  test  group  and
control  group.  The  authors  concluded  that  the  LPA  was  not
effective in preventing RHL [27].
Duteil  et  al.  [31]  conducted  a  hospital-based,  two-way
crossover study with high level of evidence in France in 1998.
All 19 participants (8 men and 11 women) applied a sunscreen-
containing LPA in and its inactive vehicle without UV filters
respectively in 2 phases of the study, which were performed at
a 4-week interval. Only 5.25% of participants (1 of 19 subjects)
had  RHL with  LPA,  whereas  57.9% (11  of  19  subjects)  had
RHL with the placebo [31].  It  was concluded that  the use of
LPA has a significant benefit in preventing RHL [31].
Rooney  et  al.  [32]  conducted  a  hospital-based  double-
blinded crossover trial with a high level of evidence in 1991.
Of the 38 participants (30 women and 8 men, 37 Caucasians
and 1 black), only 35 of them participated in both phases of the
trial. In the first phase of using placebo (n=38), the recurrence
rate of RHL was 71% (27 subjects) while the recurrence rate
was only 3% (1 subject) in the second phase of applying LPA
with an SPF 15 (n=35). All participants were followed up for
six months after study completion [32]. It was also found that
the  chance  of  reactivation  of  RHL  is  independent  of  the
previous history of recurrence [32]. The authors concluded that
the application of an LPA can effectively reduce the recurrence
rate of RHL [32].
Shulman et  al.  [33] performed a two-week observational
study on 1,062 arm personnel (1,035 men and 27 women) of
moderate level of evidence in the Mojave Desert,  the United
States in September 1983. The prevalence of RHL was 10% in
those  who did  not  use  LPA,  which  was  estimated  to  be  four
times  higher  than LPA users  [33].  However,  the  participants
applied either army-issued LPA, commercially available LPA
which were available with and without a UV filter, or no LPA
[33]. This introduced a serious limitation to the study as LPA
used  was  not  uniform  and  it  was  unclear  whether  they
contained  the  same  level  of  UV protection.  There  may  have
been impacts of confounding factors on the results, such as the
anti-desiccant effects of the LPAs. It was concluded that LPAs
containing UV filters reduce the risk of RHL [33].
Mazzarello et al.  [34] conducted a randomised crossover
trial with a high level of evidence, involving 20 participants (8
men and 12 women) between May and July 2017 in Sardinia,
Italy, as they performed daily activities for one month with an
LPA (SPF 30) or no protection [34]. Without the use of LPA,
50%  (10  subjects)  had  RHL  while  only  5%  (1  subject)  had
RHL. It  was concluded that  the  use  of  LPA was effective in
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RHL prevention [34].
Based  on  the  above  studies,  the  application  of  LPA
provides some protection in the prevention of RHL. However,
the quality of the evidence is insufficient such that considering
the  relatively  lower  SPF  of  the  LPA  used  and  the  narrow
demographic of the participants, it is questionable whether the
results  can  be  generalised  to  a  larger  population.  More  good
quality RCTs are required to ascertain the efficacy of the LPA
for the prevention of RHL.
3.3.2. Actinic Cheilitis (AC)
Three articles related to AC were included in our review
[2, 21, 35]. The studies included examined the prevalence of
AC  with  the  use  of  LPA.  However,  inter-study  variation
existed  when  determining  the  use  of  LPA  or  administering
LPA.
De Oliveira Ribeiro et al. [2] conducted a cross-sectional
observational study in Brazil among a group of fishermen and
women  to  determine  the  prevalence  of  AC.  The  use  of
sunscreen-containing LPA was observed, and findings revealed
0%  prevalence  of  AC  with  the  use  of  LPA  and  21.7%
prevalence  in  non-LPA  users  [2].  Moreover,  the  researchers
estimated a probability of  55% for AC with non-use of  LPA
and found  that  this  probability  decreased  to  35% when  LPA
was used [2].
Dos  Santos  et  al.  [35]  conducted  a  cross-sectional
observational study in Brazil among extractive mining workers
to determine the prevalence of AC. The information gathered
pertained to the use of sun protection [35]. These forms of sun
protection  included  a  hat,  a  palhoca  (improvised  individual
protection  made  of  straw constructed  in  the  workplace),  and
LPA [35]. Dos Santos et al.  found there was a prevalence of
38.4% of AC among those with some form of sun protection
and a 45.5% prevalence of AC among those with no protection
[35].  However,  when  LPA alone  was  assessed,  they  found  a
57.9% prevalence of AC with LPA use and a 36.2% prevalence
of  AC  when  no  LPA  was  used  [35].  However,  these  results
were not statistically significant [35].
De Oliveira  Bezerra  et  al.  [21]  conducted  a  comparative
RCT among a group of 23 patients who were clinically and/or
histopathologically diagnosed with AC to analyse the efficacy
of Fludroxycortide 0.125mg/g in the remission of AC signs and
symptoms.  An  LPA  with  an  SPF  of  60  was  used  in
combination  with  Fludroxycortide  in  the  test  group  of  15
participants. The control group consisted of 8 participants and
used the same LPA as in the test group. A weekly follow-up
was conducted. The control group findings revealed one patient
presented total  remission of  the lesion characteristics  of  AC,
four  demonstrated  partial  improvement,  three  exhibited  no
clinical lip alterations, and no cases presented worsening [21].
Although the participants in this study already presented with
AC before intervention and control, it is important to note that
LPA can be effective in the remission of some AC lesions [21].
Based  on  the  above  studies,  the  application  of  LPA
provides some protection in the prevention of AC. However,
further good quality RCTs are required to ascertain the efficacy
of LPA for the prevention of AC.
3.3.3. Lip Cancer (LC)
Pogoda  et  al.  [36]  used  a  verbatim  questionnaire  to
ascertain information relating to the risk of LC, including the
use of LPA. To investigate the relationship between the use of
LPA and the incidence of LC, individuals were divided based
on average UV flux [36]. Pogoda et al. found that those in the
high exposure group with an average UV flux of 430 or greater
who applied LPA no more than once a day had twice the risk
of having LC (OR=7.3) compared to those who applied LPA
more than once a day (OR=3.2) [36].
4. DISCUSSION
The  studies  included  demonstrated  that  sunscreen-
containing LPAs are effective in preventing the occurrence and
progression of these lesions. This review was hence conducted
to compile the available evidence on the effectiveness of such
agents.
In three of the included studies for RHL, more than 50% of
the participants who did not use LPA developed recurrence of
RHL, compared to less than 5% in those who used LPA, after
receiving  the  same  amount  of  UVR  exposure  [31,  32,  34].
There  was  high-quality  evidence  supporting  that  appropriate
use of LPA prevents recurrence of HL in studies by Mills et al.
and Rooney [30, 32].
However,  despite  the  evidence  supporting  the  use  of  lip
protectants in preventing RHL, interstudy variations make the
generalisation  of  the  results  to  a  larger  population  difficult.
These variations include sample characteristics, sun protection
factor of LPA, dose regimen, a diagnostic protocol for RHL,
and  geographic  differences.  With  regards  to  sample
characteristics,  the  studies  had  different  population
characteristics in age, ethnicity, gender, and amount of outdoor
activities.  This  introduces  a  source  of  heterogeneity  in  the
pooled data, lowering the applicability of the results to a larger
population. Additionally, there were variations in the strengths
of  SPF in  the  LPA used  in  these  studies.  For  example,  LPA
used in some studies [30, 32] had an SPF of 15 while another
study had an SPF of 30 [34]. One of the studies did not clarify
whether  the  LPA  used  had  any  SPF,  presenting  a  serious
limitation  to  interpretation  of  its  results  [33].  Furthermore,
variations in the dose regimen for applying LPA were found.
Participants  in  Mills  et  al.  applied  LPA hourly  while  skiing,
while those in Mazzarello et al. applied LPA every 2 hours [30,
34].  Variation  in  the  geographic  location  of  the  studies  also
limited  interstudy  analysis.  Shulman  et  al.  conducted  their
study  in  a  desert  where  a  higher  level  of  UVR  is  expected
while Mills et al. was carried out at a ski resort [30, 33]. These
interstudy  variations  introduce  limitations  in  drawing  a
universally applicable finding. Moreover, the prevalence data
obtained from the studies should be interpreted with caution.
This  is  due  to  the  possible  confounding  factors  such  as  skin
type,  occupational  exposure  to  sun,  frequency  of  RHL,  and
application routine for LPA.
As  suggested  by  all  included  studies,  UV  exposure  is
associated  with  RHL  [30  -  34].  It  is  therefore  important  to
identify the composition and application routine of LPA that
can  prevent  RHL  most  effectively.  Due  to  the  limited  data
present and heterogeneity across the studies in the composition
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and application routine of LPA, it was not possible to identify
the most ideal LPA. However, with UV filters being the critical
ingredient  in  blocking  UVR,  it  is  arguable  that  LPAs
containing higher SPF will be more effective. Further research
can be done to find the most ideal composition and regimen of
LPA.
Across the two observational studies and one RCT which
explored  the  relationship  between  the  use  of  LPAs  and  the
presence of  AC, collective data  demonstrated that  the use of
sunscreen-containing  LPAs  was  associated  with  a  lower
prevalence of AC lesions and remission of existing lesions [2,
21, 35]. All three studies for AC displayed an overall low risk
of  bias  [2,  21,  35].  However,  de  Oliveira  Ribeiro  et  al.’s
observational study presented a major flaw in the inclusion of
relevant  data,  by  failing  to  specify  whether  sunscreen  was
applied to the lips specifically, reducing the quality of evidence
significantly  [2].  While  de  Oliveira  Ribeiro  et  al.  and  dos
Santos et al. determined the relationship between AC and LPA
application, the cross-sectional nature of both the studies made
it  difficult  to  establish  a  causal  relationship  between  factor
exposure  and  disease  development,  as  well  as  difficulty  in
distinguishing new presentations of the disease from those that
have been present for some time [2]. De Oliveira Bezerra et al.
also demonstrated that LPAs may be effective in the remission
of  some  AC  lesions  [21].  However,  this  data  may  be  more
reliable  if  an  additional  group of  subjects  used a  placebo lip
agent,  containing  neither  sunscreen  nor  fludroxycortide.
Another  limitation  in  the  quality  of  evidence  resulted  due  to
missing data in de Oliveira Bezerra’s study. Although partial
improvement was seen in a subject from the group which used
fludroxycortide and LPA, adverse effects were reported [21].
Hence,  the  subject  switched  to  using  LPA  only  [21].  The
outcome of this was not reported, implying biased results [21].
Overall, there was moderate quality of evidence that LPA
use  lowers  the  incidence  of  AC.  Heterogeneity  was  evident
across the three publications mainly in regard to study type and
sample  size.  This  was  largely  influenced  by  the  study  by  de
Oliveira  Bezerra  et  al.,  which did  not  perform a  sample  size
calculation  and  included  a  small  sample  size  of  23  subjects,
making  the  results  inconclusive  to  a  larger  population  [21].
Design limitations of de Oliveira Ribeiro et al. and dos Santos
et al.’s studies contributed to the down-grading of evidence by
one level, due to being observational in nature [2, 35].
It was difficult to ascertain the reliability of the prevalence
rates obtained for AC in LPA users and LPA non-users due to
confounding factors. In the studies conducted by dos Santos et
al. and de Oliviera Ribeiro et al., length of sun exposure, other
types of sun protection apart from LPS, and age were identified
as confounding factors [2, 35]. Length of sun exposure varied
across  all  participants  which  potentially  affected  AC
prevalence.  Type  of  sun  protection  is  also  considered  a
confounding factor. For example, wearing a wide-brimmed hat
in  addition  to  LPS  would  pose  difficulty  in  determining  AC
prevalence  in  LPS  users  alone.  Age  is  another  confounding
factor to be considered as it relates to the cumulative time of
sun exposure  over  years  for  an  individual,  thus  affecting the
risk of AC development.
Across the studies, it was also important to determine an
effective LPA application routine and SPF that would benefit
in  reducing  the  prevalence  of  AC.  Dos  Santos  et  al.  and  de
Oliviera Ribeiro et al.  did not study UV-filtering ingredients
used by participants, and thus secondary outcomes could not be
measured.  Both  studies  did  agree  upon  the  fact  that  AC
prevalence was greater with lack of LPA and greater exposure
to  UVR  [2,  35].  In  contrast,  de  Oliveria  Bezerra  et  al.  had
participants in the control group who applied LPS only, with an
SPF  of  60,  before  sun  exposure  [21].  Less  than  half  of  the
participants in this control group showed no clinical signs of
improvements [21]. The majority of participants demonstrated
improved  AC  symptoms  which  illustrated  that  LPS  with  an
SPF  of  60  applied  before  sun  exposure  can  be  effective  in
preventing AC [21]. However, it cannot be concluded that an
LPA with SPF 60 is most effective in preventing AC in a wider
population due to  heterogeneity  in  results  across  the  studies.
Therefore,  further  studies  are  required  to  investigate  an
appropriate  LPA  in  the  prevention  of  AC.
It  is  widely  accepted  that  AC  is  a  potentially  malignant
disorder [7, 8, 35, 37 - 39]. As the malignant transformation of
AC can have life-threatening consequences for the individual,
prevention  of  AC  must  be  considered  a  priority.  Studies
illustrate  that  sunscreen  is  a  cost-effective  preventative  in
reducing the risk of developing malignancy by protecting the
skin  against  the  harmful  effects  of  UVR,  which  has  been
positively associated with the development of skin cancer [40 -
42].  Thus,  as  AC  is  a  potentially  premalignant  condition,
widespread awareness of AC prevention, particularly in prone
communities, should be promoted.
One  publication  investigating  the  relationship  between
LPA and LC was included in our review. Pogoda et al. found
that those living in a high UVR exposure region who applied
LPA no more than once a day had twice the risk of developing
LC (OR=7.3) compared to those who applied LPA more than
once a day (OR=3.2) [36]. There is moderate quality evidence
in this study supporting the use of LPA for the prevention of
developing lip cancer. Despite having significant findings, this
study  contains  some  limitations.  Due  to  the  nature  of  the
observational study design, participants were classified as cases
with a confirmed diagnosis of LC between 1978 and 1985 or as
controls,  who  were  frequency  matched  by  a  decade  of  birth
[36]. A verbatim questionnaire was then used in an interview to
ascertain  information on factors  that  may have increased the
chances of developing LC, including the use of LPA, among
those  already  diagnosed  with  LC  and  among  controls  [36].
Therefore,  sufficient  information  regarding  a  specific
intervention  could  not  be  ascertained  from  the  study.
Additionally,  due  to  the  nature  of  the  study  as  cases  were
already  diagnosed  with  LC,  the  results  were  presented  as  an
Odds Ratio (OR) [36]. In this case, the exposure was the use of
an LPA [36].  Risk of  bias  was introduced as  the interviewer
was  not  blinded  to  the  LC  status  of  the  participants  [36].
Furthermore, the study had a smaller sample size, reducing the
quality  of  evidence  in  regard  to  precision.  While  the
relationship between the use of an LPA and the presence of LC
was explored, it was stated that most of the participants used
coloured lipstick as the protectant [36]. Therefore, it is critical
for future studies to investigate a specific LPA with an ideal
level of SPF for the protection against LC.
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Despite significant results, some general limitations in the
studies were identified. Some studies had small sample sizes
and restricted participant demographics, which decreased the
quality  of  evidence  with  regards  to  precision  [21,  31,  34].
Some studies had a lack of blinding of either participants and
assessors which contributed to an increase in their risk of bias
[33,  35].  One  study  also  failed  to  mention  whether  the  LPA
used contained UV filters, which presented a serious limitation
to  the  overall  interpretation  of  the  result  [33].  Meta-analysis
was not possible due to interstudy heterogeneity in the method,
the type of LPA used, presentation of the results, and lack of
clinical trials looking at the prevalence of the lip lesions.
Actinic  cheilitis  and  lip  cancer  are  lip  lesions  that  can
develop  by  prolonged  exposure  to  UVR.  Recurrent  herpes
labialis  can  also  form  by  exposure  to  UVR  as  the  dormant
HSV-1 is reactivated. Our review of the current literature, with
moderate  quality  of  evidence  suggests  that  sunscreen-
containing  lip  protective  agents  can  aid  the  prevention  of
actinic cheilitis and recurrent herpes labialis.  However, there
was limited evidence for the prevention of lip cancer with only
one  study  being  included  for  review,  suggesting  the  lack  of
evidence  in  this  area.  The  most  effective  formulation  and
application  routine  for  lip  protective  agents  could  not  be
determined due to the limitations and heterogeneity across the
studies  and  can  be  the  focus  of  future  studies.  In  addition,
studies of non-English language or inaccessible full-text could
not be included in this study. The results from our review may
be  applicable  in  clinical  dentistry  with  respect  to  providing
advice  for  the  prevention  of  the  lip-associated  lesions  to
patients  at  high  risk  of  UV  exposure.
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